KRESLADI

Product

Last mentioned: Mar 19, 2026

Timeline

  1. Stock Volatility

    RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.

  2. SEC Filing 8-K

    Company enters into a new material definitive agreement and terminates a previous facility.

  3. FY 2025 Earnings

    Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.

Stories mentioning KRESLADI 1

gene-therapy Neutral

Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts

Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.

2 sources